Viatris

Yahoo Finance • 4 hours ago

David Einhorn's Greenlight Capital adds FLR, VSCO, exits VTRS, among other trades

[Finance: Businessman Holding Financial Analysis on Global Technology Network, Market Insights, Strategic Planning, Investment Opportunities.] Sumedha Lakmal/iStock via Getty Images David Einhorn's Greenlight Capital took new positions in... Full story

Yahoo Finance • 2 days ago

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vi... Full story

Yahoo Finance • 3 days ago

Monday Sector Leaders: Healthcare, Financial

Looking at the sectors faring best as of midday Monday, shares of Healthcare companies are outperforming other sectors, higher by 1.0%. Within the sector, Charles River Laboratories International Inc. (Symbol: CRL) and West Pharmaceutical... Full story

Yahoo Finance • 3 days ago

Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer

[FDA headquarters in Washington DC.] JHVEPhoto Viatris (NASDAQ:VTRS [https://seekingalpha.com/symbol/VTRS]) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic product targeting Venofer markete... Full story

Yahoo Finance • 6 days ago

EpiPen patent expiry opens new era for innovation

The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery market. Mylan acquired the rights to the injector pen for treating anaphylactic reactions following the $6.7bn acqui... Full story

Yahoo Finance • 7 days ago

Viatris Non-GAAP EPS of $0.62 beats by $0.06, revenue of $3.58B beats by $120M

* Viatris press release [https://seekingalpha.com/pr/20192714-viatris-reports-second-quarter-2025-results-and-reiterates-2025-financial-guidance] (NASDAQ:VTRS [https://seekingalpha.com/symbol/VTRS]): Q2 Non-GAAP EPS of $0.62 beats by $0.... Full story

Yahoo Finance • 9 days ago

Daily Dividend Report: BR,APO,VTRS,L,PAYC

On August 4, 2025, Broadridge's Board of Directors declared a quarterly dividend of $0.975 per share payable on October 2, 2025 to stockholders of record on September 11, 2025. This declaration reflects the Board's approval of an 11% incre... Full story

Yahoo Finance • 9 days ago

Viatris Stock: Analyst Estimates & Ratings

Viatris Inc. (VTRS), headquartered in Canonsburg, Pennsylvania, operates as a healthcare company. With a market cap of $10.3 billion, the company produces medicines for patients across a broad range of major therapeutic areas spanning both... Full story

Yahoo Finance • 14 days ago

Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health

Company Logo Discover insights with the "Glaucoma - Global Clinical Trials Review, 2025." This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, country, phase, and sponsor ty... Full story

Yahoo Finance • 15 days ago

[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Lenacapavir Injection Market size & share revenue was valued at approximately USD 3.... Full story

Yahoo Finance • 21 days ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and Sandra Leung to its Board of Directors, e... Full story

Yahoo Finance • 27 days ago

US FDA advisers vote against Otsuka's PTSD combination treatment

(Reuters) -The U.S. Food and Drug Administration’s panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma’s drug when used in combination with Viatris’ Zoloft for the treatment of adults with PTSD. The panel v... Full story

Yahoo Finance • 27 days ago

Viatris stock unchanged as Goldman maintains Neutral rating on trial miss

Investing.com - Viatris Inc (NASDAQ:VTRS), a prominent player in the pharmaceuticals industry with a market cap of $10.45 billion, maintained its Neutral rating and $10.00 price target at Goldman Sachs following disappointing clinical tria... Full story

Yahoo Finance • 27 days ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Geron Corporation, Viatris, Everus Construction, and SoundHound

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, is investigating potential violations of federal and state securities laws by certain officers and directors of Geron Corporation (NASDAQ: GERN), Viatris Inc. (NASDAQ: VT... Full story

Yahoo Finance • 27 days ago

Viatris stock falls after Phase 3 blepharitis study misses endpoint

Investing.com -- Viatris Inc. (NASDAQ:VTRS) stock fell 3.6% after the company announced that its Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint. The randomized, double-masked, vehicle-controlled trial evaluated... Full story

Yahoo Finance • 29 days ago

Otsuka’s PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting

[A pill bottle with a head on it and the words Post Traumatic Stress Disorder written below it] Inna Kot/iStock via Getty Images The FDA staffers on Wednesday cited efficacy issues related to a combination regimen involving brexpiprazole,... Full story

Yahoo Finance • 30 days ago

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma

Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now. On June 27, Viatris received approval from China’s National Medical Products Administration/NMPA for Yupelri (revefenacin) inhalation solution for the maint... Full story

Yahoo Finance • last month

ViiV expands license to produce generic Apretude in low-income countries

[GlaxoSmithKline Headquarters In Brentford, London] Leon Neal * ViiV Healthcare, which is majority owned by GSK (NYSE:GSK [https://seekingalpha.com/symbol/GSK]), said it will expand a licensing agreement with the Medicines Patent Pool t... Full story

Yahoo Finance • last month

Notable healthcare headlines for the week: Trump’s tariff threat, Merck, UnitedHealth and Moderna in focus

Wall Street’s major averages ended slightly lower last week, after posting back-to-back record closes as market participants juggled Trump's tariff announcements against a healthy appetite for technology and growth stocks. Week-to-date, t... Full story

Yahoo Finance • last month

Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT

Viatris Inc. (NASDAQ:VTRS) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on June 30, Goldman Sachs reiterated a Hold rating on Viatris Inc. (NASDAQ:VTRS) with a price target of $10.00.Viatris Inc. (VTRS): O... Full story